Page 58 - GPD-3-4

Gene & Protein in Disease Immune checkpoint blocker and NK cell activation

99. Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific cancer. Oncol Rep. 2019;42(2):839-848.
antibody collectively activates cytolytic immune cells against doi: 10.3892/or.2019.7185
multiple myeloma. Cancer Immunol Res. 2018;6(7):776-787.
106. Battaglia NG, Murphy JD, Uccello TP, et al. Combination of
doi: 10.1158/2326-6066.cir-17-0649
NKG2A and PD-1 blockade improves radiotherapy response
100. Wang Y, Li H, Xu W, et al. BCMA-targeting bispecific in radioresistant tumors. J Immunol. 2022;209(3):629-640.
antibody that simultaneously stimulates NKG2D- doi: 10.4049/jimmunol.2100044
enhanced efficacy against multiple myeloma. J Immunother.
2020;43(6):175-188. 107. Bogen JP, Carrara SC, Fiebig D, Grzeschik J, Hock B,
Kolmar H. Design of a trispecific checkpoint inhibitor and
doi: 10.1097/cji.0000000000000320
natural killer cell engager based on a 2 + 1 common light
101. Basher F, Dhar P, Wang X, et al. Antibody targeting tumor- chain antibody architecture. Front Immunol. 2021;12:669496.
derived soluble NKG2D ligand sMIC reprograms NK cell doi: 10.3389/fimmu.2021.669496
homeostatic survival and function and enhances melanoma
response to PDL1 blockade therapy. J Hematol Oncol. 108. Dougan M, Ingram JR, Jeong HJ, et al. Targeting cytokine
2020;13(1):74. therapy to the pancreatic tumor microenvironment using
PD-L1-specific VHHs. Cancer Immunol Res. 2018;6(4):389-401.
doi: 10.1186/s13045-020-00896-0
doi: 10.1158/2326-6066.cir-17-0495
102. Deng Q, Lee M, Fattah F, Koyama S, Gerber D, Akbay E.
YIA23-001: Targeting NKG2D ligands is therapeutically 109. Jiang G, Ng YY, Tay JCK, et al. Dual CAR-T cells to
effective in NSCLC. J Natl Comprehensive Cancer Netw. treat cancers co-expressing NKG2D and PD1 ligands in
2023;21(3.5):YIA23-001-YIA23-001. xenograft models of peritoneal metastasis. Cancer Immunol
Immunother. 2023;72(1):223-234.
doi: 10.6004/jnccn.2022.7136
doi: 10.1007/s00262-022-03247-9
103. Shen MJ, Xu LJ, Yang L, et al. Radiation alters PD-L1/
NKG2D ligand levels in lung cancer cells and leads to 110. Kang TH, Mao CP, He L, et al. Tumor-targeted delivery of
immune escape from NK cell cytotoxicity via IL-6-MEK/ IL-2 by NKG2D leads to accumulation of antigen-specific
Erk signaling pathway. Oncotarget. 2017;8(46):80506-80520. CD8+ T cells in the tumor loci and enhanced anti-tumor
effects. PLoS One. 2012;7(4):e35141.
doi: 10.18632/oncotarget.19193
doi: 10.1371/journal.pone.0035141
104. Xu L, Chen X, Shen M, et al. Inhibition of IL-6-JAK/
Stat3 signaling in castration-resistant prostate cancer 111. Pan M, Wang F, Nan L, et al. αVEGFR2-MICA fusion
cells enhances the NK cell-mediated cytotoxicity via antibodies enhance immunotherapy effect and synergize
alteration of PD-L1/NKG2D ligand levels. Mol Oncol. with PD-1 blockade. Cancer Immunol Immunother.
2018;12(3):269-286. 2023;72(4):969-984.
doi: 10.1002/1878-0261.12135 doi: 10.1007/s00262-022-03306-1
105. Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M. 112. Chung YM, Tsai WB, Khan PP, et al. FOXO3-dependent
Effect of platinumbased chemotherapy on the expression suppression of PD-L1 promotes anticancer immune
of natural killer group 2 member D ligands, programmed responses via activation of natural killer cells. Am J Cancer
cell death1 ligand 1 and HLA class I in nonsmall cell lung Res. 2022;12(3):1241-1263.

Volume 3 Issue 4 (2024) 10 doi: 10.36922/gpd.3804